The study developed monoclonal antibodies utilizing the human MFAP5 recombinant protein as an antigen in mice and hybridoma clones’ antibodies was analyzed for their specificity murine and human MFAP5. The scientists used an Octet RED384 system to dictate the binding affinity kinetics and also, the preciseness of the antibody clones. This was accompanied by functional characterization and epitope mapping by in vitro assays. The therapeutic potency of a lead anti-MFAP5 clone 130A in tumor suppression was analyzed by pancreatic tumor—ovarian tumor-bearing mouse models.